Catabasis Pharmaceuticals to Present at Upcoming Scientific and Advocacy Conferences
New Directions in Biology and Disease of
Skeletal Muscle Conferenceto be held June 25– June 28, 2018in New Orleans, LA, at The Westin New Orleans Canal Place. Andrew Nichols, Ph.D., Chief Scientific Officer of Catabasis, will give an oral presentation titled “Edasalonexent, an NF-kB Inhibitor in Development as a Potential Disease-Modifying Therapy for Duchenne Muscular Dystrophy” on Monday, June 25, 2018, from 3:10pm– 3:40pm ETin the Grand Ballroomon the 12th floor.
2018 PPMD Annual
Connect Conferenceto be held June 28– June 30, 2018in Scottsdale, AZ, at The Phoenician. Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis, will present “MoveDMD: Phase 2 Trial of Edasalonexent, an NF-κB Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy” during the poster session on Thursday, June 28, 2018, at 6:30pm MSTand an oral presentation on Friday, June 29, 2018, from 2:20pm-2:40pm MST.
International Congress on Neuromuscular Diseasesto be held July 6– July 10, 2018in Vienna, Austria, at the Hilton Vienna Am Stadtpark. Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis, will present “Rationale for Edasalonexent Dose Schedule in Phase 2 of the MoveDMD Trial” during the poster session on Saturday, July 7, 2018, from 17:15 – 18:30 CESTin the Exhibit Hall.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small molecule that is being developed as a potential disease-modifying therapy for all patients affected by DMD, regardless of their underlying mutation. Edasalonexent inhibits NF-kB, a protein that is activated in DMD and drives inflammation, fibrosis and muscle degeneration and suppresses muscle regeneration. Edasalonexent continues to be dosed in an open-label extension of the MoveDMD Phase 2 clinical trial, and Catabasis is preparing for a single global Phase 3 trial to evaluate the efficacy and safety of edasalonexent for registration purposes, dependent on raising capital. The
Investor and Media Contact
Catabasis Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971